Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitrous Oxide in Treatment-Resistant Major Depression
NCT02994433Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2017
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of nitrous oxide in major depressive disorder (MDD) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Comparison of functional connectivity between default mode network of treatment-resistant depressed and non-depressed participants at 2 hours, Comparison of functional connectivity between affective network of treatment-resistant depressed and non-depressed participants at 2 hours and 2 more. Started Jan 2017; status: recruiting.
02
Drugs
nitrous oxide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02994433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994433.